November 04, 2024
Developing treatments for people with mental health conditions
October 09, 2024
Boehringer Ingelheim collaborates with Circle Pharma
October 08, 2024
Boehringer receives U.S. FDA Breakthrough Therapy designation for MASH
September 16, 2024
Topline results from Boehringer's Phase III IPF Study
September 09, 2024
Positive results reported in HER2 mutated lung cancer
August 27, 2024
Boehringer Ingelheim to unveil oncology research at WCLC
July 18, 2024
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
July 18, 2024
New affordability initiative with GoodRx for our biosimilar
July 17, 2024
New effort to help improve C-R-M health outcomes
June 07, 2024
Results from Phase II MASH trial presented at EASL 2024
June 01, 2024
Boehringer inhalers now available at $35 a month for eligible patients
May 13, 2024
New agreement with Quallent expands biosimilar access
May 02, 2024
Improving Access to Clinical Trials
May 01, 2024
FDA Approves Additional Formulation of Our Biosimilar
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline.
April 06, 2024
Results announced from EMPACT-MI phase III trial
March 19, 2024
New FDA approval for the treatment of GPP
March 12, 2024
Update on sNDA for fibrosing ILD in children and adolescents
March 07, 2024
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
February 26, 2024
Top-line Phase II Data for treatment of MASH
November 20, 2023
National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)
November 10, 2023
Investigational Compound Granted FDA Orphan Drug Designation
November 06, 2023
Promising Phase II Results in Chronic Kidney Disease
November 04, 2023
AI-Driven Model Validated to Predict Risk of CKD Progression
November 01, 2023
Hip-Hop Classic “It Takes Two” Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease
October 30, 2023
Life forward - Boehringer Ingelheim unveils its evolved company brand
October 27, 2023
Boehringer Ingelheim wins 2023 Prix Galien USA
October 02, 2023
Low-WAC interchangeable biosimilar is now available
September 22, 2023
FDA Approved Treatment Option for Adults with CKD
August 28, 2023
Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program
August 02, 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
July 25, 2023
FDA accepts OFEV sNDA for 6–17-year-olds with fibrosing ILD
July 13, 2023
Interchangeable Biosimilar Now on Express Scripts® Formulary
July 04, 2023
Boehringer Ingelheim presents Effisayil™ 2 trial results
July 01, 2023
Interchangeable biosimilar now available in the U.S.
June 28, 2023
Boehringer Ingelheim and FIT Unveil Fifth Piece for The Unwearable Collection
June 23, 2023
Optum Rx Places Interchangeable Biosimilar on its Commercial Formulary
June 21, 2023
FDA approves treatment option for T2D in children 10 and older
May 22, 2023
FDA approves autoinjector pen for Interchangeable biosimilar
May 09, 2023
IL-11 inhibitor antibody clinical development launched
May 02, 2023
U.S. FDA Grants Breakthrough Therapy designation
April 01, 2023
J-Code Issued for SPEVIGO
March 29, 2023
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
March 08, 2023
FDA accepts Jardiance sNDA for T2D in children 10 and older
March 06, 2023
Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines
February 28, 2023
Boehringer Ingelheim announces new partnership to support awareness of GPP
January 20, 2023
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease.
January 09, 2023
New cancer therapeutics collaboration with 3T Bio
December 19, 2022
Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia
December 07, 2022
Full data announced in DINAMO trial in young people with T2D
November 16, 2022
Boehringer Ingelheim Welcomes New 2023 GOLD Report Positioning LAMA/LABA as the Preferred Treatment for the Majority of Patients with COPD
November 04, 2022
Full data announced in phase III EMPA-KIDNEY trial
October 26, 2022
First patient enrolled in FIBRONEER™-IPF Phase III trial
October 17, 2022
Boehringer Ingelheim announces expanded access program
September 25, 2022
Boehringer Ingelheim announces InPedILD PhaseIII trial results
September 21, 2022
Boehringer Ingelheim introduces Tune In To Lung Health
September 01, 2022
FDA approves the first treatment option for generalized pustular psoriasis flares in adults
August 03, 2022
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
June 05, 2022
Real-world data announced for adults with type 2 diabetes
June 02, 2022
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
May 15, 2022
Investigational treatment slowed lung function decline in IPF
May 03, 2022
Boehringer Ingelheim Statement on Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
April 20, 2022
Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
April 05, 2022
Boehringer Ingelheim strengthens investment in R&D
March 16, 2022
Phase III EMPA-KIDNEY trial will stop early
February 24, 2022
FDA Grants Breakthrough Therapy Designation for IPF
December 15, 2021
U.S. FDA grants priority review for spesolimab for the treatment of flares in patients with generalized pustular psoriasis (GPP), a rare, life-threatening skin disease
December 13, 2021
Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner
November 16, 2021
Boehringer Ingelheim’s Carine Boustany Appointed to BIO Board
November 11, 2021
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction
November 08, 2021
Weill Cornell Medicine and NewYork-Presbyterian Hospital join Boehringer Ingelheim to study the incidence of progressive Interstitial Lung Disease in COVID-19 patients
November 05, 2021